As a result, a market for cheaper, off-brand versions of their active ingredients — semaglutide and tirzepatide — has ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide ...

The supply of GLP-1 drugs for weight loss and diabetes treatment is expected to tighten this week with a federal deadline to ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

The FDA has been cut off from producing compounded weight-loss drugs such as Ozempic, Mounjaro or Wegovy, the most effective ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Compounded GLP-1s are no longer to be sold following the FDA announcement that the shortage of semaglutide and tirzepatide ended.

A major 72-week trial shows tirzepatide leads to double-digit weight loss and greater waist reduction than semaglutide, reshaping obesity treatment strategies and offering new hope for patients ...

Tirzepatide and semaglutide are highly effective medications for obesity management. The efficacy and safety of tirzepatide as compared with semaglutide in adults with obesity but without type 2 ...

The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...

Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.